InvestorLens

OLMA — OLEMA PHARMACEUTICALS INC

Public company

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying OLMA?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 2 buying vs 0 selling last quarter
69
Macro Tailwind
Macro conditions are mixed for this sector
52
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their OLMA position last quarter, 2 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Squeeze regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Ken Griffin, Stanley Druckenmiller)
  • +4 tracked investors reported holding OLMA at their latest filing
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About OLEMA PHARMACEUTICALS INC (OLMA)

OLEMA PHARMACEUTICALS INC (OLMA) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $34M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in OLMA

100
/100
Strong Institutional Accumulation
Added / Increased2
Reduced0
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track OLMA

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

OLMA Ownership Composition

How OLEMA PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
95% of tracked value
Institutions
4
tracked investors
Total Reported
$35.6M
combined 13F value
Sectors2
  • Other95.4%
  • Hedge Funds4.6%
Other(3)
95.4%
Hedge Funds(1)
4.6%

Tracked investors reporting OLMA

  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    1.1M
    Value
    $16.5M
    % Portfolio
    0.00%
  • Stanley DruckenmillerMar 31, 2026
    Duquesne Family Office
    Shares
    986.8K
    Value
    $14.7M
    % Portfolio
    0.44%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    182.9K
    Value
    $2.7M
    % Portfolio
    0.00%
  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    109.7K
    Value
    $1.6M
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold OLMA?
4 tracked institutional investors disclosed a position in OLMA (OLEMA PHARMACEUTICALS INC) in their most recent 13F filing.
Who is the largest institutional holder of OLMA?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in OLMA, valued at $34M.
Did institutional ownership of OLMA increase or decrease?
Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 fully exited OLMA.
Where does this OLMA ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
OLMA (OLEMA PHARMACEUTICALS INC) — Institutional Holders & — InvestorLens